A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Clinical trial NCT07313891 · WITHDRAWN

Trial details

NCT number: NCT07313891
Sponsor: Relmada Therapeutics, Inc.
Status: WITHDRAWN
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) Cancer Urothelial Carcinoma Bladder Urologic Cancer

Start date: 2026-05-01
Primary completion: 2029-09-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.